A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Titre officiel

A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Sommaire:

The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandrogen therapy and have not received chemotherapy for mCRPC.

Description de l'essai

Primary Outcome:

  • Number of participants with adverse events (AEs)
  • Number of deaths
  • Radiographic progression-free survival (rPFS) assessed by blinded independent central review (BICR) per Prostate Cancer Working Group 3 (PCWG3)
Secondary Outcome:
  • Objective response rate per Prostate Cancer Working Group 3 (ORR-PCWG3)
  • Time to response per Prostate Cancer Working Group 3 (TTR-PCWG3) as determined by BICR
  • Duration of response per Prostate Cancer Working Group 3 (DOR-PCWG3) as determined by BICR
  • Prostate-specific antigen response rate (PSA-RR)
  • Time to prostate-specific antigen progression (TTP-PSA) per PCWG3
  • Overall survival (OS)
  • Number of participants with adverse events (AEs)
  • Number of deaths

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer